suPAR in the assessment of post intensive care unit prognosis: a pilot study

suPAR na avaliação do prognóstico após permanência na unidade de terapia intensiva: um estudo piloto

INTRODUCTION

In-hospital death following intensive care unit (ICU) discharge has been estimated to be 5% - 27%, and nearly 10% of discharged patients require ICU readmission.\(^1\)\(^4\) Despite improvements in ICU care quality and widespread utilization of step-down units over the last decades, a significant number of patients still die in the hospital following successful ICU discharge;\(^1\)\(^5\) therefore, adequate evaluation is necessary to identify individuals at high risk for unfavorable outcomes.

ABSTRACT

Objective: To determine the performance of soluble urokinase-type plasminogen activator receptor upon intensive care unit discharge to predict post intensive care unit mortality.

Methods: A prospective observational cohort study was conducted during a 24-month period in an 8-bed polyvalent intensive care unit. APACHE II, SOFA, C-reactive protein, white cell count and soluble urokinase-type plasminogen activator receptor on the day of intensive care unit discharge were collected from patients who survived intensive care unit admission.

Results: Two hundred and two patients were included in this study, 29 patients (18.6%) of whom died after intensive care unit discharge. Nonsurvivors were older and more seriously ill upon intensive care unit admission with higher severity scores, and nonsurvivors required extended use of vaspressors than did survivors.

The area under the receiver operating characteristics curves of SOFA, APACHE II, C-reactive protein, white cell count, and soluble urokinase-type plasminogen activator receptor at intensive care unit discharge as prognostic markers of hospital death were 0.78 (95%CI 0.70 - 0.86); 0.70 (95%CI 0.61 - 0.79); 0.54 (95%CI 0.42 - 0.65); 0.48 (95%CI 0.36 - 0.58); and 0.68 (95%CI 0.58 - 0.78), respectively. SOFA was independently associated with a higher risk of in-hospital mortality (OR 1.673; 95%CI 1.252 - 2.234), 28-day mortality (OR 1.861; 95%CI 1.856 - 2.555) and 90-day mortality (OR 1.584; 95%CI 1.241 - 2.022).

Conclusion: At intensive care unit discharge, soluble urokinase-type plasminogen activator receptor is a poor predictor of post intensive care unit prognosis.

Keywords: Receptors, urokinase plasminogen activator; C-reactive protein; Biomarkers; Prognosis

Conflicts of interest: None.

Submitted on February 3, 2018
Accepted on July 4, 2018

Corresponding author:
Joana Silvestre
Unidade de Cuidados Intensivos Polivalente
Hospital de São Francisco Xavier
Centro Hospitalar Lisboa Ocidental
Estrada do Forte do Alto do Duque, 1449-005
Lisboa, Portugal
E-mail: joanapsilvestre@gmail.com

Responsible editor: Jorge Ibrain Figueira Salluh
DOI 10.5935/0103-507X.20180062
Several severity scores have been developed, such as the Acute Physiology and Chronic Health Evaluation II (APACHE II) score,\(^6\) the mortality probability model,\(^7\) the Simplified Acute Physiology Score II (SAPS II),\(^8\) and more recently, the SAPS 3.\(^9\) Almost all severity scores use a group of demographic, clinical and physiological variables from the first day of the ICU stay to obtain an individual patient score and a prediction of in-hospital mortality. Typically, the abovementioned severity scores are used to monitor the performance of a single ICU, to adjust mortality of different ICUs to its case-mix and for helping to guide resource allocation.\(^10\) The currently available models are not useful and were neither designed nor validated for individual patient management.\(^11,12\) These scores were also not designed to evaluate post ICU discharge prognosis.\(^2,7,13-16\)

Some investigators advocate that the pro- or anti-inflammatory status of the patient could be used as a potential risk factor upon ICU discharge.\(^17,18\) Biomarkers, such as C-reactive protein (CRP), procalcitonin (PCT) and lactate, have been studied with respect to hospital and ICU outcomes with conflicting results.\(^19-21\)

Systemic levels of soluble urokinase-type plasminogen activator receptor (suPAR), a protein derived from cleavage and release from neutrophils, lymphocytes, endothelial and malignant cells, has recently been recognized as a potential prognostic biomarker of infectious disease.\(^22\) Various studies have been conducted on suPAR, the majority of which have focused on the ability of suPAR to predict sepsis and mortality in patients with bacteremia, systemic inflammatory response syndrome, sepsis, and septic shock.\(^23-26\) Systemic levels of suPAR have been found to be significantly higher in critically ill patients who exhibit poor outcomes.\(^27\) The role of suPAR as a prognostic marker of hospital mortality after ICU discharge has yet to be evaluated. Systemic levels of suPAR remain elevated long after clinical recovery, declining only after several weeks.\(^28\) Therefore, suPAR appears to be a promising prognostic marker in critically ill patients.

The aim of our study was to determine the predictive value of suPAR in the assessment of outcome (hospital mortality) of patients discharged alive from the ICU.

**METHODS**

We conducted a prospective, single center, observational study over 24 months (June 2011 - June 2013) at the ICU of Hospital de São Francisco Xavier, an 8-bed multidisciplinary ICU.

The local Ethics Committee approved the study design, and informed consent was obtained from all patients or legal representative before study inclusion.

All patients discharged alive from the ICU were included, except for those with age < 18 years, those transferred to another ICU, and those with a do not resuscitate order.

Patients were followed until hospital death or hospital discharge.

Patient survival at 28 and 90 days after ICU discharge was also analyzed.

Data collected included admission diagnosis and past medical history. Vital signs were evaluated hourly, and daily extremes were recorded. APACHE II was calculated 24 hours after ICU admission.

C-reactive protein levels and white cell count (WCC) were measured at admission and daily until discharge. suPAR levels and SOFA scores were collected upon ICU discharge.

Measurement of CRP was performed using an immunoturbidimetric method (Tina-quant CRP; Roche Diagnostics, Mannheim, Germany).

suPAR was measured using a venous blood sample collected into an EDTA tube, centrifuged and frozen at -80°C. Measurements were performed in duplicate using an enzyme-linked immunosorbent assay (suPARnostic\(^8\), ViroGates, Lyngby, Denmark) following the manufacturer’s instructions. The lower limit of detection was 1.1ng/mL.

Subgroup analysis was performed in patients with sepsis diagnoses. Sepsis was defined according to 2001 international consensus definitions.\(^29\)

**Statistical analysis**

Data are presented as the mean ± standard deviation (SD). Categorical variables are presented as rates or percentages. Comparisons of parametric variables between groups were performed with an unpaired Student’s t-test, and nonparametric variables were compared between groups using a Mann-Whitney test.

To compare the predictive value of the biomarkers and severity scores, receiver-operating characteristic (ROC) curves were built and the area under the curve (AUC) was determined. DeLong was applied to determine the statistical significance of the differences between the AUC values.
The primary outcome variable was post ICU mortality. To study the effect of biomarkers and SOFA on mortality, we used logistic regression. The unadjusted odds ratio (OR) and the corresponding 95% confidence interval (95%CI) were computed for each variable.

The level of statistical significance was set at 0.05 and all tests were two-tailed. We used the Statistical Package for Social Science (SPSS) statistical software package, version 19.0 (SPSS, Inc., Chicago, IL, USA) for all statistical analyses.

RESULTS

A total of 202 patients (112 women and 90 men) were included, with a mean age of 65.3 ± 16.3 years and a mean APACHE II score of 22.0 ± 9.0. Post ICU hospital mortality rate was 14.6%, and hospital readmission rate was 38.4%.

Nonsurvivors were older and more seriously ill, with higher severity scores, and requiring more vasopressors than survivors. We did not find significant differences in admission diagnoses between groups. Clinical and demographic characteristics are presented in table 1.

At ICU discharge, nonsurvivors were sicker, had higher SOFA scores (p < 0.001) and presented with higher suPAR levels (p = 0.003) than survivors. The other biomarkers (C-reactive protein and WCC levels) were similar between the two groups (Table 2).

Among the studied prognostic variables, the best predictors of post ICU mortality were APACHE II (AUC 0.70) and SOFA (AUC 0.78). The ROC curve for suPAR yielded an AUC of 0.68 (p = 0.002), which was higher than the AUCs for CRP (AUC 0.54) and WCC (AUC 0.48).

The combination of suPAR with APACHE and SOFA increased predictive ability (Table 3). Despite the improvement in mortality prediction, predictive ability did not reach a combined sensitivity or specificity above 80%.

Multivariate logistic regression analysis was performed with post ICU in-hospital mortality as the dependent variable. We included the following five variables in this model: APACHE II, SOFA, CRP, suPAR, and WCC (Table 4). SOFA was independently associated with a higher risk of in-hospital mortality (OR 1.673; 95%CI 1.252 - 2.234), 28-day mortality (OR 1.861; 95%CI

Table 1 - Baseline characteristics of patients

|                | All (N = 202) | Survivors (N = 173) | Nonsurvivors (N = 29) | p values |
|----------------|--------------|---------------------|-----------------------|----------|
| Age (years)    | 65.6 ± 16.3  | 64.3 ± 16.6         | 73.7 ± 12.2           | 0.004    |
| Sex (M/F)      | 90/112       | 77/96               | 13/16                 | NS       |
| APACHE II      | 22.0 ± 9.0   | 21.2 ± 8.7          | 26.9 ± 9.0            | 0.002    |
| Admission diagnosis |          |                     |                       |          |
| Respiratory    | 81           | 67                  | 14                    |          |
| Cardiovascular | 33           | 25                  | 8                     |          |
| Renal          | 16           | 13                  | 14                    |          |
| Neurological   | 15           | 14                  | 1                     |          |
| Gastroenterological | 10        | 9                   | 1                     |          |
| Surgical       | 9            | 8                   | 1                     |          |
| Trauma         | 6            | 6                   | 0                     |          |
| Metabolic      | 5            | 0                   | 0                     |          |
| Others         | 27           | 26                  | 1                     |          |
| ICU length of stay (days) | 8.8 ± 22.4 | 8.7 ± 24.4          | 9.7 ± 8.8             | NS       |
| Hospital length of stay (days) | 32.1 ± 35.3 | 29.8 ± 35.7         | 38.8 ± 32.5           | NS       |
| Sepsis         | 97 (48.0)    | 82 (47.4)           | 15 (51.7)             | NS       |
| Mechanical ventilation (days) | 3.2 ± 6.0 | 2.9 ± 5.8           | 4.9 ± 7.8             | NS       |
| Renal replacement therapy (days) | 1.4 ± 3.3 | 1.2 ± 3.0           | 2.8 ± 4.8             | NS       |
| Vasopressor (days) | 1.1 ± 1.9 | 0.9 ± 1.5           | 2.3 ± 3.4             | < 0.001  |

M/F - male/female; APACHE - Acute Physiology and Chronic Health Evaluation; ICU - intensive care unit; NS - nonsignificant. P value for comparison between survivors and nonsurvivors. The results are expressed as mean ± standard deviation, n, or number (%).
Table 2 - Biomarker levels and Sequential Organ Failure Assessment at intensive care unit discharge

| Index variable | All (N = 202) | Survivors (N = 173) | Nonsurvivors (N = 29) | p values |
|----------------|---------------|---------------------|-----------------------|----------|
| suPAR (ng/mL)  | 7.7 ± 4.3     | 7.4 ± 4.1           | 9.9 ± 4.8             | 0.003    |
| CRP (ng/dL)    | 7.1 ± 6.0     | 7.1 ± 6.1           | 7.3 ± 5.1             | NS       |
| WCC (1000/mL)  | 10.5 ± 4.9    | 10.6 ± 5.0          | 9.9 ± 4.0             | NS       |
| SOFA           | 2.7 ± 1.7     | 2.4 ± 1.6           | 4.1 ± 1.3             | < 0.001  |

suPAR - soluble urokinase-type plasminogen activator receptor; CRP - C-reactive protein; WCC - white cell count; SOFA - Sequential Organ Failure Assessment; NS - nonsignificant. The results are expressed as the mean ± standard deviation.

Table 3 - Receiver operating characteristic curve analysis showing the prognostic power of biomarkers and severity scores in predicting mortality

| Index variable | AUC   | 95%CI         | p value |
|----------------|-------|---------------|---------|
| suPAR          | 0.685 | 0.586 - 0.785 | 0.002   |
| CRP            | 0.538 | 0.423 - 0.649 | 0.538   |
| WCC            | 0.476 | 0.365 - 0.586 | 0.679   |
| APACHE II      | 0.699 | 0.606 - 0.793 | 0.001   |
| SOFA           | 0.780 | 0.702 - 0.850 | 0.000   |
| suPAR + APACHE II | 0.721 | 0.630 - 0.812 | 0.045   |
| suPAR + SOFA   | 0.803 | 0.734 - 0.872 | 0.000   |

AUC - area under the curve; 95%CI - 95% confidence intervals; suPAR - soluble urokinase-type plasminogen activator receptor; CRP - C-reactive protein; WCC - white cell count; APACHE - Acute Physiology and Chronic Health Evaluation; SOFA - Sequential Organ Failure Assessment. Discrimination is presented as area under the curve with 95% confidence intervals. DeLong analysis was applied to determine the statistical significance of the difference between the areas under the curve. AUCs of different variables were compared to the AUC of SOFA.

Table 4 - Odds ratios and confidence interval limits of biomarkers and clinical scores at intensive care unit discharge as well as 28 days and 90 days after intensive care unit discharge

| Index variable | OR    | 95%CI         | p value |
|----------------|-------|---------------|---------|
| suPAR          | 1.060 | 0.965 - 1.165 | 0.233   |
| CRP            | 0.980 | 0.906 - 1.065 | 0.639   |
| WCC            | 1.000 | 1.000 - 1.000 | 0.336   |
| APACHE II      | 1.036 | 0.991 - 1.085 | 0.128   |
| SOFA           | 1.873 | 1.252 - 2.334 | < 0.001 |
| suPAR*         | 0.987 | 0.887 - 1.098 | 0.786   |
| CRP*           | 0.906 | 0.815 - 1.006 | 0.735   |
| WCC*           | 1.000 | 1.000 - 1.000 | 0.023   |
| APACHE II*     | 1.008 | 0.959 - 1.059 | 0.519   |
| SOFA*          | 1.861 | 1.356 - 2.555 | < 0.001 |
| suPAR†         | 0.988 | 0.905 - 1.079 | 0.786   |
| CRP†           | 0.988 | 0.921 - 1.060 | 0.735   |
| WCC†           | 1.000 | 1.000 - 1.000 | 0.023   |
| APACHE II†     | 1.014 | 0.972 - 1.058 | 0.519   |
| SOFA†          | 1.584 | 1.241 - 2.022 | < 0.001 |

OR - odds ratio; 95%CI - 95% confidence interval; suPAR - soluble urokinase-type plasminogen activator receptor; CRP - C-reactive protein; WCC - white cell count; APACHE - Acute Physiology and Chronic Health Evaluation; SOFA - Sequential Organ Failure Assessment; 28 days post intensive care unit mortality; 90 days post intensive care unit mortality.

Table 5 - Odds ratios and confidence interval limits of biomarkers and clinical scores at intensive care unit discharge in septic patients

| Index variable | OR    | 95%CI         | p value |
|----------------|-------|---------------|---------|
| suPAR          | 1.112 | 0.977 - 1.265 | 0.109   |
| CRP            | 0.956 | 0.862 - 1.073 | 0.397   |
| WCC            | 1.000 | 1.000 - 1.000 | 0.333   |
| APACHE II      | 1.018 | 0.965 - 1.085 | 0.513   |
| SOFA           | 1.876 | 1.238 - 2.842 | 0.003   |

OR - odds ratio; 95%CI - 95% confidence interval; suPAR - soluble urokinase-type plasminogen activator receptor; CRP - C-reactive protein; WCC - white cell count; APACHE - Acute Physiology and Chronic Health Evaluation; SOFA - Sequential Organ Failure Assessment.

1.856 - 2.555) and 90-day mortality (OR 1.584; 95%CI 1.241 - 2.022).

Documented sepsis was present in 101 patients (50%). The presence of sepsis did not influence post ICU outcome, with similar mortality rates between septic and nonseptic patients. Similarly, to the general patient population, only SOFA score was associated with poor outcome and with a higher risk of hospital mortality (OR 1.876; 95%CI 1.238 - 2.842) (Table 5).

DISCUSSION

In this prospective observational study, we evaluated the performance of suPAR levels taken upon ICU discharge to predict post ICU mortality. Our data show that suPAR levels at ICU discharge are higher in hospital nonsurvivors.

In addition to the accuracy of suPAR in assessing the risk of post ICU mortality being lower than current severity scores, and its combination with these scores only slightly improved predictive ability for post ICU mortality.
Some investigators advocate that post ICU death is related to a persistent inflammatory response, with endothelial dysfunction and microcirculatory abnormalities present in nonsurvivors who have higher biomarkers levels.\(^{(30)}\)

Various biomarkers have been proposed to be of potential use in prognostication. CRP concentrations have been extensively used and correlate with ongoing organ dysfunction, ICU mortality and likely also with bacterial burden.\(^{(31-33)}\) This marker is routinely measured in the ICU and has advantages of simplicity, reproducibility and speed.\(^{(31,34)}\)

C-reactive protein has been studied as a prognostic biomarker for in-hospital mortality and readmission after ICU discharge.\(^{(17,18,20)}\) Because these results are seemingly conflicting, there is no evident consensus for using serum CRP and other biomarkers for post ICU prognosis.\(^{(19,20,30)}\)

Recently, higher suPAR and pro-adrenomedullin (proADM) levels upon ICU admission seemed to be correlated to hospital mortality in septic patients.\(^{(35)}\) Similar to our data, in this study, prognostic accuracy was significantly better for severity scores than for any of the analyzed biomarkers. The best AUC for the prediction of in-hospital mortality was generated using APACHE II (0.82) and SOFA (0.75) scores. The ROC curve for suPAR yielded an AUC of 0.67, which was higher than those of proADM (0.62), CRP (0.50) or PCT (0.44). The combination of severity scores and biomarkers did not improve AUCs.

More recently, Jalkanen et al. studied a cohort of critically ill nonsurgical patients and found that low suPAR concentrations were predictive of survival.\(^{(36)}\) However, in that study, neither classical biomarkers nor severity scores were compared for the assessment of risk mortality.

Our study analyzed suPAR levels at ICU discharge. The biological characteristics of suPAR, which are only slightly influenced by circadian changes and remain stable in systemic circulation within the first days of a sepsis course, might explain its superiority over other biomarkers, namely, CRP and PCT.\(^{(27)}\)

However, in our study, suPAR levels, despite being increased in hospital nonsurvivors, were not associated with higher risk of death either alone or in combination with severity scores. In addition, suPAR levels did not show any correlation with post ICU mortality in septic patients.

We found that a single determination of suPAR upon ICU discharge was a better tool for predicting in-hospital mortality than CRP. However, the prognostic accuracy was significantly better for APACHE II or SOFA scores than for any of the analyzed biomarkers. The combination of biomarkers with these severity scores only slightly improved their prognostic accuracies. Like other biomarkers, suPAR as a single biomarker is not a strong enough predictor for clinical decision-making.

**CONCLUSION**

In the present study, we compared severity scoring systems and biomarkers for predicting mortality in patients discharged alive from intensive care units. Despite suPAR levels being slightly better than those of common biomarkers, including C-reactive protein, they did not exhibit superior performance than severity scores. At intensive care unit discharge, suPAR is a poor predictor of post intensive care unit prognosis.

**ACKNOWLEDGMENTS**

ViroGates A/S, Denmark, donated the ELISA kits for measuring suPAR free of charge. The company had no influence on study design, the results, or the decision to publish results.

The authors would like to thank Ana Ramos Dias and Luis Rodrigues for their collaboration on laboratory measurements.
RESUMO

Objetivo: Determinar o desempenho da dosagem do receptor ativador de plasminogênio tipo uroquinase solúvel quando da alta da unidade de terapia intensiva para predição da mortalidade após permanência na mesma unidade.

Métodos: Durante 24 meses conduziu-se um estudo prospectivo observacional de coorte em uma unidade de terapia intensiva polivalente de oito leitos. Colheram-se os seguintes dados: APACHE II, SOFA, níveis de proteína C-reativa e receptor ativador de plasminogênio tipo uroquinase solúvel, além de contagem de leucócitos no dia da alta da unidade de terapia intensiva, em pacientes que sobreviveram à permanência na unidade de terapia intensiva.

Resultados: Durante este período, incluíram-se no estudo 202 pacientes; 29 (18,6%) morreram após alta da unidade de terapia intensiva. Os não sobreviventes eram mais idosos e tinham enfermidades mais graves quando admitidos à unidade de terapia intensiva, com escores de severidade mais elevados, e necessitaram de vasopressores por mais tempo do que os que sobreviveram. As áreas sob a curva Característica de Operação do Receptor para SOFA, APACHE II, proteína C-reativa, contagem de leucócitos e receptor ativador de plasminogênio tipo uroquinase solúvel, no momento da alta da unidade de terapia intensiva, avaliadas como marcadores de prognóstico de morte hospitalar, foram, respectivamente, 0,78 (IC95% 0,70 - 0,86); 0,70 (IC95% 0,61 - 0,79); 0,54 (IC95% 0,42 - 0,65); 0,48 (IC95% 0,36 - 0,58); 0,68 (IC95% 0,58 - 0,78). O SOFA associou-se de forma independente com risco mais elevado de morte no hospital (OR 1,673; IC95% 1,252 - 2,234), assim como para mortalidade após 28 dias (OR 1,861; IC95% 1,856 - 2,555) e mortalidade após 90 dias (OR 1,584; IC95% 1,241 - 2,022).

Conclusão: A dosagem do receptor ativador de plasminogênio tipo uroquinase solúvel na alta unidade de terapia intensiva teve um valor prognóstico fraco de mortalidade após a permanência nesta unidade.

Descritores: Receptores de ativador de plasminogênio tipo uroquinase; Proteína C-reativa; Biomarcadores; Prognóstico

REFERENCES

1. Rosenberg AL, Watts C. Patients readmitted to ICUs: a systematic review of risk factors and outcomes. Chest. 2000;118(2):492-502.
2. Moreno R, Vincent JL, Matos R, Mendonca A, Cantraine F, Thijs L, et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med. 1999;25(7):686-96.
3. Williams TA, Dobb GJ, Finn JC, Webb SA. Long-term survival from intensive care: a review. Intensive Care Med. 2005;31(10):1306-15.
4. Brinkman S, de Jonge E, Abu-Hanna A, Arbous MS, de Lange DW, de Keizer NF. Mortality after hospital discharge in ICU patients. Crit Care Med. 2013;41(5):1229-36.
5. Makris N, Dullhunty JM, Paratz JD, Bandeche H, Gowardman JR. Unplanned early readmission to the intensive care unit: a case-control study of patient, intensive care and ward-related factors. Anaesth Intensive Care. 2010;38(4):723-31.
6. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818-29.
7. Lemeshow S, Le Gall JR. Modeling the severity of illness of ICU patients. A systems update. JAMA. 1994;272(13):1049-55.
8. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270(24):2957-63. Erratum in: JAMA 1994;271(17):1321.
9. Moreno RP, Metnitz PG, Almeida E, Jordan B, Bauer R, Campos RA, Lipichino G, Edbrooke D, Capuzzo M, Le Gall JR; SAPS 3 Investigators. SAPS 3—From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med. 2005;31(10):1345-55. Erratum in: Intensive Care Med. 2006;32(5):796.
10. Gunning K, Rowan K. ABC of intensive care: outcome data and scoring systems. BMJ. 1999;319(7204):241-4.
11. Cullen DJ, Chernow B. Predicting outcome in critically ill patients. Crit Care Med. 2002;24(9):1345-8.
12. Afessa B, Gajic O, Keegan MT. Severity of illness and organ failure assessment in adult intensive care units. Crit Care Clin. 2007;23(3):639-58.
13. Rogers J, Fuller HD. Use of daily Acute Physiology and Chronic Health Evaluation (APACHE) II scores to predict individual patient survival rate. Crit Care Med. 1994;22(9):1402-5.
14. Castella X, Artigas A, Bion J, Kari A. A comparison of severity of illness scoring systems for intensive care unit patients: results of a multicenter, multinational study. The European/North American Severity Study Group. Crit Care Med. 1995;23(8):1327-35.
15. Beck DH, Taylor BL, Millar B, Smith GB. Prediction of outcome from intensive care: a prospective cohort study comparing Acute Physiology and Chronic Health Evaluation II and III prognostic systems in a United Kingdom intensive care unit. Crit Care Med. 1997;25(11):1942-9.
16. Glance LG, Oster T, Shinozaki T. Intensive care unit prognostic scoring systems to predict death: a cost-effectiveness analysis. Crit Care Med. 1998;26(11):1842-9.
17. Ho KM, Dobb GJ, Lee KY, Towler SC, Webb SA. C-reactive protein concentration as a predictor of intensive care unit readmission: a nested case-control study. J Crit Care. 2006;21(3):259-65.
18. Ho KM, Lee KY, Dobb GJ, Webb SA. C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge: a prospective cohort study. Intensive Care Med. 2008;34(3):481-7.
19. Silvestre J, Coelho L, Póvoa P. Should C-reactive protein concentration at ICU discharge be used as a prognostic marker? BMC Anesthesiol. 2010;10:17.
20. Araújo J, Gonçalves-Pereira J, Teixeira S, Nazareth R, Silvestre J, Mendes V, et al. Assessment of risk factors for in-hospital mortality after intensive care unit discharge. Biomarkers. 2012;17(2):180-5.
21. Matsumura Y, Nakada TA, Abe R, Oshima T, Oda S. Serum procalcitonin level and SOFA score at discharge from the intensive care unit predict post-intensive care unit mortality: a prospective study. PLoS One. 2014;9(12):e114007.
22. Kofod K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care. 2007;11(2):R38.
23. Huttunen R, Syrjänen J, Vuento R, Hurme M, Huhtala H, Laine J, et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteremia: a prospective cohort study. J Intern Med. 2011;270(1):32-40.

24. Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteremia and predicts mortality. Clin Microbiol Infect. 2004;10(5):409-15.

25. Yilmaz G, Köksal I, Karahan SC, Mentese A. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome. Clin Biochem. 2011;44(14-15):1227-30.

26. Mölkänen T, Ruotsalainen E, Thorball CW, Järvinen A. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2011;30(11):1417-24.

27. Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med. 2012;38(9):1418-28.

28. Donadello K, Scolletta S, Covajes C, Vincent JL. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012;10:2.

29. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29(4):530-8.

30. Yende S, D’Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, Kong L, Carter M, Angus DC. GenIMMS Investigators. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008;177(11):1242-7.

31. Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Mélot C, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest. 2003;123(6):2043-9.

32. Orati JA, Almeida P, Santos V, Ciofia G, Lobo SM. Serum C-reactive protein concentrations in early abdominal and pulmonary sepsis. Rev Bras Ter Intensiva. 2013;25(1):6-11.

33. Póvoa P, Salluh JI. Use of biomarkers in sepsis: many questions, few answers. Rev Bras Ter Intensiva. 2013;25(1):1-2.

34. Enguix A, Rey C, Concha A, Medina A, Coto D, Díezgo MA. Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. Intensive Care Med. 2001;27(1):211-5.

35. Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibañez M. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med. 2013;39(11):1945-52.

36. Jalkanen V, Yang R, Linko R, Huhtala H, Oikonen M, Varpula T, Pettillä V, Tenhunen J; FINNALI Study Group. SuPAR and PAI-1 in critically ill, mechanically ventilated patients. Intensive Care Med. 2013;39(3):489-96.